Indian Facility Warned for Repeat Sterility Concerns

Drug Industry Daily
A A
The FDA issued a warning letter to Fresenius Kabi for GMP violations observed at its manufacturing facility in Himachal Pradesh, India, citing a failure to investigate sterility issues.

To View This Article:

Login

Subscribe To Drug Industry Daily